Advanced Biomedical Research

The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury

Authors

1 Department of Neurosurgery, Al Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Neurology, Al Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

3 Farzan Institute of Clinical Research, Tehran, Iran

Abstract

Background: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain
injury (TBI).
Materials and Methods: This study is designed as a randomized double-blind placebo-controlled with 100 patients suffered from DAI. CsA was administered to the intervention group (n = 50) as 5 mg/kg/24 h via 250 ml dextrose water (DW) 5% solution (DW 5%) during the first 8 h after trauma. The control group (n = 50) received only DW 5% in the same course. The presenting Glasgow coma scale in addition to the Glasgow outcome scale-extended (GOS-E) and mini-mental state examination (MMSE) in the 3 rd and 6 th months after trauma were documented. The serum values for complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were checked to assess for complications.
Results: Most patients in both groups had type II DAI (46%). There was no significant difference between groups in the GOS-E scores after 3 and 6 months. All participants were in moderate or severe classes of MMSE with no statistically significant difference. Except for the higher BUN level in the cyclosporine treated group, 48 h after admission (P = 0.012), the difference in the level of Cr, AST, ALT, and ALP was not significant and all were in the normal range. The CBC results showed only significant difference for White Blood Cell (WBC) count at 12 h (P = 0.000).
Conclusion: The administration of CsA is not effective in the improvement of consciousness and cognitive function. However, it brings about no adverse effects.

Keywords

1. Thurman D. Epidemiology and economics of head trauma. In: Miller LP, Hayes RL, editors. Head Trauma: Basic, preclinical, and clinical directions. New York: Wiley-Liss; 2001. p. 327-47.  Back to cited text no. 1
    
2. Adams JH, Graham DI, Murray LS, Scott G. Diffuse axonal injury due to nonmissile head injury in humans: An analysis of 45 cases. Ann Neurol 1982;12:557-63.  Back to cited text no. 2
    
3. Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR. Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma 2002;19:829-41.  Back to cited text no. 3
    
4. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004;36:257-64.  Back to cited text no. 4
    
5. Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 2000;17:843-55.  Back to cited text no. 5
    
6. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.  Back to cited text no. 6
    
7. Okonkwo DO, Büki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 1999;10:353-8.  Back to cited text no. 7
    
8. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab 1999;19:443-51.  Back to cited text no. 8
    
9. Scheff SW, Sullivan PG. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma 1999;16:783-92.  Back to cited text no. 9
    
10. Albensi BC, Sullivan PG, Thompson MB, Scheff SW, Mattson MP. Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol 2000;162:385-9.  Back to cited text no. 10
    
11. Riess P, Bareyre FM, Saatman KE, Cheney JA, Lifshitz J, Raghupathi R, et al. Effects of chronic, post-injury Cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury. Restor Neurol Neurosci 2001;18:1-8.  Back to cited text no. 11
    
12. Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. Cyclosporin Adisposition following acute traumatic brain injury. J Neurotrauma 2006;23:109-16.  Back to cited text no. 12
    
13. Mazzeo AT, Kunene NK, Gilman CB, Hamm RJ, Hafez N, Bullock MR. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. J Neurotrauma 2006;23:962-75.  Back to cited text no. 13
    
14. Mazzeo AT, Alves OL, Gilman CB, Hayes RL, Tolias C, Niki Kunene K, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: A microdialysis study. Acta Neurochir (Wien) 2008;150:1019-31.  Back to cited text no. 14
    
15. Hatton J, Rosbolt B, Empey P, Kryscio R, Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008;109:699-707.  Back to cited text no. 15
    
16. Mazzeo AT, Brophy GM, Gilman CB, Alves OL, Robles JR, Hayes RL, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: Results from a prospective randomized trial. J Neurotrauma 2009;26:2195-206.  Back to cited text no. 16
    
Advanced Biomedical Research
Volume 2014, January
January 2014
Pages 1-6